Manish R. Patel | Hematology Oncology | Minneapolis, MN

QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors

Enrollment Status: Recruiting

Publish Date: January 29, 2025

Intervention Type: Drug

Study Drugs: N-803, Pembrolizumab, Nivolumab, Atezolizumab, Avelumab, Durvalumab, PD-L1 t-haNK

Study Phase: Phase 2

A Randomized Double Blind Phase II Trial of Restorative Microbiota Therapy (RMT) in Combination With Durvalumab (MEDI4736) and Chemotherapy in Untreated Patients With Advanced or Metastatic Adenocarcinoma Non-Small Cell Lung Cancer

Enrollment Status: Recruiting

Publish Date: January 20, 2025

Intervention Type: Other, Drug

Study Drugs: Restorative Microbiota Therapy, Durvalumab, Cisplatin+Pemetrexed or Carboplatin+Pemetrexed

Study Phase: Phase 2

Phase II Trial of Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland Carcinoma: Big Ten Cancer Research Consortium BTCRC-HN17-111

Enrollment Status: Recruiting

Publish Date: October 15, 2024

Intervention Type: Drug

Study Drugs: Goserelin acetate, Pembrolizumab

Study Phase: Phase 2

Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Patients With Select Solid Tumors

Enrollment Status: Recruiting

Publish Date: October 02, 2024

Intervention Type: Biological

Study Drugs: VV1, Cemiplimab

Study Phase: Phase 2

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer

Enrollment Status: Active_not_recruiting

Publish Date: February 20, 2025

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

An Open-Label, Multicenter Follow-up Study to Collect Long-term Data on Participants From Multiple Avelumab (MSB0010718C) Clinical Studies

Enrollment Status: Active_not_recruiting

Publish Date: February 06, 2025

Intervention Type: Drug

Study Drug: Avelumab

Study Phase: Phase 3

An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

Enrollment Status: Active_not_recruiting

Publish Date: January 09, 2025

Intervention Type: Drug

Study Drug: Entrectinib

Study Phase: Phase 2

A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma

Enrollment Status: Active_not_recruiting

Publish Date: December 20, 2024

Intervention Type: Drug

Study Drugs: LXH254, LTT462, Trametinib, Ribociclib

Study Phase: Phase 2

Pivotal Study of Subcutaneous Tibial Nerve Stimulation With eCoin for Overactive Bladder (OAB) With Urgency Urinary Incontinence (UUI)

Enrollment Status: Completed

Publish Date: October 16, 2024

Intervention Type: Device

Study Phase: Not Applicable

A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

Enrollment Status: Active_not_recruiting

Publish Date: October 02, 2024

Intervention Type: Drug

Study Drugs: LOXO-305, Rituximab

Study Phase: Phase 1/Phase 2

A Phase 1b, Open-Label, Dose-Escalation, Dose-Expansion Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: August 09, 2024

Intervention Type: Drug

Study Drugs: SM08502, Abiraterone, Prednisone, Docetaxel, FOLFIRI Protocol, Panitumumab

Study Phase: Phase 1

An Open-Label, Randomized-Sequence, Multicenter, Single-Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Formulation Compared to Niraparib Capsule Formulation in Patients With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: July 25, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Multicenter, Open-label Rollover Study of Sitravatinib Alone or in Combination With Other Anticancer Therapies in Patients With Advanced or Metastatic Solid Malignancies

Enrollment Status: Active_not_recruiting

Publish Date: June 21, 2024

Intervention Type: Drug

Study Phase: Phase 2/Phase 3

Phase 1b Dose-Finding Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 in Patients With Advanced or Metastatic Cancer

Enrollment Status: Active_not_recruiting

Publish Date: May 29, 2024

Intervention Type: Drug

Study Drugs: Niraparib, TSR-042 Anti-PD-1 Antibody, Bevacizumab, TSR-022 Anti-TIM-3 Antibody, Carboplatin, Pemetrexed, Nab-Paclitaxel

Study Phase: Phase 1

Phase 1b/2 Open-label Study to Evaluate the Safety, Tolerability and Efficacy of Rivoceranib or Trifluridine/Tipiracil as Monotherapies and Rivoceranib and Trifluridine/Tipiracil as Combination Therapy in Subjects With Metastatic Colorectal Cancer

Enrollment Status: Terminated

Publish Date: May 02, 2024

Intervention Type: Drug

Study Phase: Phase 1

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: April 23, 2024

Intervention Type: Drug

Study Phase: Phase 1

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Atezolizumab in Subjects With Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: April 22, 2024

Intervention Type: Drug

Study Phase: Phase 1

Phase 1 Open-Label Dose Escalation Study of BDB001 as a Single Agent and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors

Enrollment Status: Active_not_recruiting

Publish Date: February 01, 2024

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Enrollment Status: Completed

Publish Date: December 21, 2023

Intervention Type: Biological

Study Drugs: MGD013, MGD013+Margetuximab

Study Phase: Phase 1

An Open-label Phase 1b Study of ORIC-101 in Combination With Anticancer Therapy in Patients With Advanced or Metastatic Solid Tumors

Enrollment Status: Terminated

Publish Date: December 15, 2023

Intervention Type: Drug

Study Phase: Phase 1

A Phase IB/II Study of Nivolumab In Combination With ALT-803 In Patients With Pretreated, Advanced, or Metastatic Non-Small Cell Lung Cancer

Enrollment Status: Completed

Publish Date: March 07, 2023

Intervention Type: Biological

Study Drugs: ALT-803, Nivolumab

Study Phase: Phase 1/Phase 2

A Phase 1 Study of an ERK1/2 Inhibitor (LY3214996) Administered Alone or in Combination With Other Agents in Advanced Cancer

Enrollment Status: Completed

Publish Date: November 22, 2022

Intervention Type: Drug

Study Phase: Phase 1

MasterKey-01: A Phase 1/2, Open-label, Two-part, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics & Antitumor Activity of BDTX-189, an Inhibitor of Allosteric ErbB Mutations, in Patients w/ Advanced Solid Malignancies

Enrollment Status: Terminated

Publish Date: October 14, 2022

Intervention Type: Drug

Study Drug: BDTX-189

Study Phase: Phase 1/Phase 2

Ph1 Study of the Safety, PK, and PDn of Escalating Oral Doses of the Glutaminase Inhibitor CB-839, as a Single Agent and in Combination With Standard Chemotherapy in Patients With Advanced and/or Treatment-Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: July 20, 2022

Intervention Type: Drug

Study Phase: Phase 1

Phase 1 Trial of Vesicular Stomatitis Virus Genetically Engineered to Express NIS and Human Interferon Beta (VSV-IFNβ-NIS) Monotherapy and in Combination With Avelumab, in Patients With Refractory Solid Tumors

Enrollment Status: Completed

Publish Date: April 27, 2022

Intervention Type: Biological

Study Phase: Phase 1

A Phase 1, Two-Cohort, Open-Label, Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With Locally Recurrent or Metastatic ER+ Breast Cancer

Enrollment Status: Completed

Publish Date: December 15, 2021

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Enrollment Status: Terminated

Publish Date: December 08, 2021

Intervention Type: Drug

Study Drugs: INCB053914, I-DAC (Intermediate Dose Cytarabine), Azacitidine, Ruxolitinib

Study Phase: Phase 1/Phase 2

A Phase 1, First-in-Human, Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors.

Enrollment Status: Completed

Publish Date: December 03, 2021

Intervention Type: Drug

Study Phase: Phase 1

Psychometric Evaluation of a Patient-Reported Symptom Index for Non-Muscle Invasive Bladder Cancer: Field Testing

Enrollment Status: Completed

Publish Date: October 13, 2021

A Prospective, Non-Randomized, Parallel Cohort, Multi-Center Study of Xenform vs. Native Tissue for the Treatment of Women With Anterior/Apical Pelvic Organ Prolapse

Enrollment Status: Completed

Publish Date: April 14, 2021

Intervention Type: Procedure

Study Phase: Not Applicable

A Two-part Phase I, Open Label, Dose Escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Pyrotinib in Patients With HER2-positive Solid Tumors Whose Disease Progressed on Prior HER2 Targeted Therapy

Enrollment Status: Unknown

Publish Date: February 01, 2021

Intervention Type: Drug

Study Drug: Pyrotinib

Study Phase: Phase 1

A Randomized Phase 2 Trial of AM0010 in Combination With Pembrolizumab vs. Pembrolizumab Alone as First-Line (1L) Therapy in Patients With Stage IV / Metastatic Wild Type (WT) Non-Small Cell Lung Cancer and Tumors With High Expression of PD-L1 (> 50%)

Enrollment Status: Terminated

Publish Date: January 20, 2021

Intervention Type: Drug, Biological

Study Phase: Phase 2

A Phase 1-2 Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors

Enrollment Status: Terminated

Publish Date: November 02, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1-2 Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies

Enrollment Status: Terminated

Publish Date: November 02, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5745 as Monotherapy and in Combination With Chemotherapy in Subjects With Advanced Solid Tumors

Enrollment Status: Completed

Publish Date: June 02, 2020

Intervention Type: Drug

Study Phase: Phase 1

A Phase 1b Trial of LY2606368 in Combination With Chemotherapy or Targeted Agents in Advanced and/or Metastatic Tumors

Enrollment Status: Completed

Publish Date: April 01, 2020

Intervention Type: Drug

Study Phase: Phase 1

Phase I Dose-Escalation, Safety, Pharmacokinetic and Pharmacodynamic Study of BVD-523 in Patients With Advanced Malignancies

Enrollment Status: Completed

Publish Date: March 20, 2020

Intervention Type: Drug

Study Phase: Phase 1/Phase 2

A Phase 2, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer

Enrollment Status: Completed

Publish Date: July 18, 2019

Intervention Type: Drug

Study Phase: Phase 2

A Phase 1/1b Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Clinical Activity of Defactinib in Combination With Avelumab in Epithelial Ovarian Cancer

Enrollment Status: Terminated

Publish Date: April 30, 2019

Intervention Type: Drug

Study Phase: Phase 1

A Phase I Study of VS-4718, a Focal Adhesion Kinase Inhibitor, in Subjects With Metastatic Non-Hematologic Malignancies

Enrollment Status: Terminated

Publish Date: July 28, 2017

Intervention Type: Drug

Study Phase: Phase 1

Dr. Manish R. Patel

Overview

Insurance

Locations

Clinical Research

40 Clinical Trials

Fairview Express Care

Fairview Express Care

Fairview Express Care

Areas of Expertise